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Abstract: Bioactive components, due in part to their epigenetic properties, are beneficial for
preventing several human diseases including cerebrovascular pathologies. However, no clear
demonstration supports the idea that these molecules still conserve their epigenetic effects when
acting at very low concentrations reproducing the brain levels achieved after oral administration
of a micronutrient supplement. In the present study, we used a cellular model of brain
ischemia to investigate the neuroprotective and epigenetic activities of a commercially available
micronutrient mixture (polyphenol-enriched micronutrient mixture, PMM) enriched in polyphenols
((-)-epigallocatechin-3-gallate, quercetin, resveratrol), α-lipoic acid, vitamins, amino acids and other
micronutrients. Mimicking the suggested dietary supplementation, primary cultures of mouse
cortical neurons were pre-treated with PMM and then subjected to oxygen glucose deprivation
(OGD). Pre-treatment with PMM amounts to provide bioactive components in the medium in the
nanomolar range potently prevented neuronal cell death. The protection was associated with the
deacetylation of the lysin 310 (K310) on NF-κB/RelA as well as the deacetylation of H3 histones at
the promoter of Bim, a pro-apoptotic target of ac-RelA(K310) in brain ischemia. Epigenetic regulators
known to shape the acetylation state of ac-RelA(K310) moiety are the histone acetyl transferase
CBP/p300 and the class III histone deacetylase sirtuin-1. In view of that evidence, the protection we
here report unveils the efficacy of bioactive components endowed with either inhibitory activity on
CBP/p300 or stimulating activity on the AMP-activated protein kinase–sirtuin 1 pathway. Our results
support a potential synergistic effect of micronutrients in the PMM, suggesting that the intake of a
polyphenol-based micronutrient mixture can reduce neuronal vulnerability to stressful conditions at
concentrations compatible with the predicted brain levels reached by a single constituent after an
oral dose of PMM.
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1. Introduction
Bioactive components have been extensively studied for their beneficial activities in preventing
widespread human diseases, including cerebrovascular dysfunctions [1,2]. Bioactive components can
modulate different epigenetic targets, including the histone acetylation/deacetylation balance, through
the regulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities [3–5].
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Acetylation of histones by HATs typically enhances transcription by reducing the affinity between
DNA and histones, while the removal of acetyl groups by HDACs results in chromatin condensation,
leading to the repression of gene transcription [6]. Notably, aberrant acetylation status resulting from
the misregulation of HAT and/or HDAC activity has been associated with different pathologies,
including brain ischemia [7].
Besides histones, HATs and HDACs can also modulate the acetylation state of a number of
transcription factors, including NF-κB [8]. In the central nervous system, NF-κB plays a crucial
role in regulating genes controlling either cell survival [9] or the apoptosis and inflammation
associated with neurodegeneration [10]. We previously demonstrated that mechanisms affecting
the acetylation state of the NF-κB/RelA subunit in brain ischemia can discriminate between protective
and neurotoxic activation of the transcriptional factor [11]. Protective ischemic preconditioning and
harmful ischemia induce similar levels of p50/RelA activation, but only the ischemic injury induces
atypical RelA acetylation. The RelA that translocates to the nucleus in primary cortical neurons
exposed to preconditioning oxygen and glucose deprivation (OGD) or in cortices of mice subjected
to preconditioning middle cerebral artery occlusion (MCAO) shows a general lysine deacetylation.
Conversely, as demonstrated by mutagenesis analysis, the RelA activated in neurons exposed to lethal
OGD or in the cortices of mice subjected to noxious ischemia displays a general lysine deacetylation,
but a site-specific acetylation at the lysine 310 (K310) residue [12,13]. The aberrant RelA acetylation in
neurons subjected to OGD was associated with reduced histone acetylation and with the transcription
of the pro-apoptotic Bim gene, as indicated by increased H3 acetylation at the Bim promoter [14–16].
The aberrantly acetylated RelA co-immunoprecipitated with the HAT p300/CBP, suggesting a role of
p300/CBP in K310 acetylation during the lethal exposure of neuronal cells to OGD [12].
In the present work, we investigated the neuroprotective activity of a polyphenol-enriched
micronutrient mixture (PMM), containing (-)-epigallocatechin-3-gallate (EGCG), quercetin, resveratrol,
α-lipoic acid (LA), vitamins, amino acids and other micronutrients in primary mouse cortical neurons
exposed to OGD. In addition, we studied the epigenetic mechanisms involved in the activity of
the bioactive components mixture by focusing on the acetylation state of either HAT or HDAC
target proteins.
2. Materials and Methods
2.1. PMM Composition
In this study, we tested the neuroprotective effect of the antioxidant supplements contained in
MyAntiOxidant (MA) and the multivitamin supplements contained in MyHealth (MH) (Meetab Srl,
Milan, Italy). MA and MH were generously gifted by Meetab Srl. The daily recommended dose of
the supplements is 4 tablets of MA (https://www.meetab.it/en/23-antiossidante.html) and 1 tablet
of MH (https://www.meetab.it/en/22-my-health.html). The supplement powders, in accordance
with the manufacturer’s recommendations, were mixed at the ratio MA:MH = 4:1mg to obtain the
PMM. Table 1 shows the composition of the combined multivitamin and antioxidant supplement.
The compositions of MA and MH have been certified by the manufacturer in terms of the quality
and concentration of raw materials, the exclusion of GMO (genetically modified organism), radiation
procedure and contaminants listed in the Annex II regulations (EU) No 1169/2011 (http://meetab.it/
certificates/CoAs_My-AntiOxidant.pdf; https://www.meetab.it/certificates/CoAs_My-Health.pdf;
see also supplementary file). Briefly, a daily dose of MA and MH supplements contains 850.00 mg of
polyphenols and LA, 1272.66 mg of vitamins, 1222.50 mg of amino acids, 454.00 mg of fruit and plant
extracts and 140.63 mg of mineral salts.
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Table 1. Polyphenol-enriched micronutrient mixture (PMM) composition.
PMM Components Amount per Daily Dose (mg) Content per 100 mg (%)
Polyphenols and α-lipoic acid 850.00 21.57
green tea extract (40% EGCG) 500.00 (200.00) 12.69 (5.08)
quercetin 150.00 3.81
α-lipoic acid 150.00 3.81
resveratrol 50.00 1.27
Vitamins 1272.66 32.30
vitamin C (*) 890.00 22.59
vitamin E (**) 120.00 3.05
vitamin B3 (***) 70.00 1.78
vitamin B1 50.00 1.27
vitamin B6 (****) 18.00 0.46
β-carotene 14.00 0.36
others 110.66 2.81
Amino acids 1222.50 31.03
L-lysine 525.00 13.33
L-glutamine 150.00 3.81
L-proline 120.00 3.05
N-acetyl L-cysteine 110.00 2.79
L-arginine 105.00 2.67
L-methionine 105.00 2.67
glycine 60.00 1.52
others 47.50 1.21
Fruits and Plants extract 454.00 11.52
broccoli extract 150.00 3.81
others 304.00 7.72
Mineral salts 140.63 3.57
calcium (*****) 50.00 1.27
potassium (citrate) 30.00 0.76
zinc (amino acid chelated) 12.50 0.32
magnesium (citrate) 10.00 0.25
manganese (gluconate) 8.00 0.20
phosphorus (******) 8.00 0.20
others 22.12 0.56
Total 3939.79 100.00
(*) 550 mg ascorbic acid / 300 mg calcium ascorbate / 40 mg ascorbyl palmitate; (**) 80 mg α-tocopherol / 20 mg
mixed α-, β-, γ-, δ- tocopherols/20 mg mixed tocotrienols; (***) 60 mg nicotinamide / 10 mg nicotinic acid (****)
as pyridoxal 5′-phosphate; (*****) derived from 40 mg calcium carbonate and 10 mg calcium phosphate; (******)
derived from calcium phosphate.
2.2. PMM Preparation
Based on literature data, we estimated that the possible neuroprotective effect of the PMM against
anoxic insults could be mediated by the presence of green tea in the supplement and, in particular,
of EGCG, the polyphenol present in the greatest quantity in the green tea [17–22], together with other
bioactive components present in large quantities in the mixture. The PMM concentrations tested in the
present study are reported in Table 2 with the corresponding contents of main bioactive components.
PMM was dissolved in dimethyl sulfoxide (DMSO) and diluted before application to a final DMSO
concentration lower than 0.3%.
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Table 2. PMM concentrations and corresponding contents of the main bioactive components.
Nutrients Concentrations
PMM (pg/mL) 0.00884 0.0265 0.265 0.884 2.65 26.5
EGCG (nM) 0.0010 0.0030 0.030 0.10 0.30 3.0
quercetin (nM) 0.0011 0.0033 0.033 0.11 0.33 3.3
α-lipoic acid (nM) 0.0016 0.0049 0.049 0.16 0.49 4.9
resveratrol (nM) 0.0005 0.0015 0.015 0.05 0.15 1.5
vitamin C (nM) 0.0089 0.0268 0.268 0.89 2.68 26.8
vitamin E (nM) 0.0006 0.0019 0.019 0.06 0.19 1.9
vitamin B6 (nM) 0.0002 0.0005 0.005 0.02 0.05 0.5
N-acetyl L-cysteine (nM) 0.0015 0.0045 0.045 0.15 0.45 4.5
2.3. Cell Culture
Primary cultures of mouse cortical neurons were prepared from 15-day-old embryonic C57Bl/6
mice (Charles River, Calco, Italy) and maintained in culture as previously described [23,24]. All animal
studies were approved by the Animal Research Committees of the University of Brescia and followed
Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on
the protection of animals used for scientific purposes. Cells were plated at a density of 2.0 × 106
cells in 21 cm2 culture dishes (Nunc, Germany) for Western blot (WB) analyses, 2.2 × 105 cells in
2 cm2 culture dishes for the viability studies and 9 × 106 cells in 56 cm2 culture dishes for the
chromatin-immunoprecipitation (ChIP) assay.
2.4. OGD and Measurement of Lactate Dehydrogenase (LDH) Release
Primary cortical neurons were exposed from day 7 in vitro (DIV) to different concentrations
of PMM ranging from 0.00884 to 26.5 pg/mL (corresponding to the following contents of the main
bioactive components: EGCG 0.0010–3.0 nM; quercetin 0.0011–3.3 nM; LA 0.0016–4.9 nM; resveratrol
0.0005–1.5 nM; vitamin C 0.0089–26.8 nM; vitamin E 0.0006–1.9 nM; vitamin B6 0.0002–0.5 nM; N-acetyl
L-cysteine 0.0015–4.5 nM). The treatments were renewed at every change of media. The same amount
of DMSO contained in the PMM was used as a vehicle.
OGD was carried out at DIV 11, as previously described [23,24]. Briefly, cells were incubated
with deoxygenated glucose-free balanced salt solution and transferred to an air-tight chamber fluxed
with 95% N2 and 5% CO2 for 10 min to reach an oxygen concentration lower than 0.4%. Cortical
neurons were exposed to OGD for 3 h. A parallel set of cultured neurons were incubated for 3 h with a
normal oxygenated, balanced salt-solution containing glucose and used as a control. After the anoxic
incubation, neurobasal medium containing 0.4% B27 supplement was added to cortical neurons for
24 h to allow recovery under normoxic conditions. At the end of the recovery period, we estimated the
neuronal injury by assessing the ratio between the amount of lactate dehydrogenase (LDH) released in
culture medium and the total releasable LDH using the CytoTox 96® Non-Radioactive Cytotoxicity
Assay (Promega, Fitchburg, WI, USA). All the experiments were run in triplicate.
2.5. WB and Co-Immunoprecipitation (co-IP) Assays
Nuclear protein extracts were prepared as previously described [16] from primary cortical neurons
exposed to 3 h OGD and 2 h recovery in culture medium. WB analyses and co-IP studies were
carried out as previously described [16]. For WB analyses, nuclear proteins (20 µg) were resolved
by Bolt™ 4–12% Bis-Tris Plus SDS/polyacrylamide pre-cast gels (Invitrogen, Carlsbad, CA, USA).
Immunodetection was performed by incubating the membrane overnight at 4 ◦C with the following
primary antibodies: rabbit anti-Acetyl H3 (K9-18) (#07-593, Upstate-Millipore, Burlington, MA,
USA), rabbit anti-Acetyl H4 (K16) (#06-762, Upstate-Millipore), rabbit anti-H3 (#9715, Cell Signaling
Technology, Danvers, MA, USA) and rabbit anti-H4 (#07-108, Upstate-Millipore). For co-IP
analyses, 40 µg of nuclear extracts were incubated at 4 ◦C overnight with 2 µg of goat anti-RelA
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antibody (#sc-372GX, Santa Cruz Biotechnology, Dallas, TX, USA), and co-immunoprecipitated
proteins were detected by WB using the following antibodies: rabbit anti-Acetyl-RelA (K310)
(#3045, Cell Signaling Technology), rabbit anti-Acetyl-K (#06-933, Upstate-Millipore) and rabbit
anti-RelA (#sc-372, Santa Cruz Biotechnology). Quantification of protein expression was performed by
densitometric analysis of immunoblots using Gel Pro.3 analysis software (MediaCybernetics, Rockville,
MD, USA).
2.6. ChIP Assay
ChIP assays were performed in primary cortical neurons, as previously described [16]. To study
H3 histone acetylation at the Bim promoter in neuronal cultures exposed to 3 h OGD and then 2 h
recovery in culture medium, we used a ChIP assay kit (#9003S, Cell Signaling Technology). The sheared
chromatin was incubated with anti-acetyl H3 (K9/18) or anti-IgG (negative control) overnight at
4 ◦C. An aliquot of chromatin, not incubated with antibody, was used as the input control sample.
Antibody-bound protein/DNA complexes were washed, eluted, treated with proteinase digest proteins
and subjected to real-time polymerase chain reaction (qRT-PCR) analyses. The specific primers used to
amplify the mouse Bim promoter were as follows:
forward, 5-CTGGATGCAGGTTGGGTAG-3
reverse, 5 GGGAATGAGAAAGTTAGCTGGA-3.
These specific primers generated a 410-bp product. Incorporation of the SYBR Green dye into the
PCR products was monitored in real-time with a ViiA™ 7 Real-Time PCR detection system (Applied
Biosystems, Bedford, MA, USA), allowing the determination of the threshold cycle (CT) at which the
exponential amplification of PCR products began. CT values were normalized over corresponding CT
values obtained by IgG immunoprecipitation and further normalized over relative CT values obtained
in input (no antibody) chromatin. Final data obtained in neurons exposed to OGD (with or without
pretreatment with PMM) were then normalized to data obtained in control neurons.
2.7. Statistical Analysis
Data are expressed as mean± standard error, and the statistical significance of differences between
groups was evaluated by one-way ANOVA followed by Dunnett’s multiple comparison test using
GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, CA, USA) p < 0.05 was considered
to be significant.
3. Results
3.1. Pre-Treatment with PMM Elicits Neuroprotection in Cortical Neurons Exposed to OGD
We previously showed that in primary cultures of mouse cortical neurons exposed to OGD,
apoptosis precedes necrosis. This was indicated by the early TUNEL-positivity displayed by the cells
within 6 h after the OGD and the parallel release of cytochrome c in the cytosol in the absence of LDH
release. Subsequent necrosis causes progressive elevation of the extracellular LDH level that becomes
clearly detectable in the culture medium 24 h after the OGD exposure [15,25]. Starting from the DIV 7,
PMM or vehicle were added to the culture medium of cortical neurons and maintained until the end
of the OGD recovery (DIV 12). At DIV 11, cortical neurons were exposed to 3 h OGD followed by 24 h
of recovery (Figure 1A—experimental protocol). The treatment with PMM at concentrations ranging
from 0.884 to 26.5 pg/mL reduced cell death by 40% (Figure 1B).
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Figure 1. Pre-treatment with the polyphenol-enriched micronutrient mixture (PMM) promotes
neuroprotection in cortical neurons exposed to oxygen and glucose deprivation (OGD).
(A) Experimental protocol for lactate dehydrogenase (LDH) toxicity assay in cortical neurons.
Cells were pre-treated ith the PMM at day in vitro (DIV) 7. At DIV 11, cells were exposed to 3 h of OGD
and then maintained in recovery medium for 24 h. The mixture was renewed at every change of media.
(B) LDH assay was performed at the end of the 24 h of recovery. Different doses of PMM were used in
cells. DMSO was used as vehicle in c ntrol cells (neurons exposed to OGD). The neurotoxicity of the
PMM-treat neurons is represented as a percentage relative to the neurotoxicit in the vehicle-treated
neurons (OGD-exposed neurons), arbitrarily set at 100%. The ef ective neuroprotective doses of the
mixture were 0.884, 2.65 and 26.5 pg/mL, which co responded to the following doses of the main
bioactiv components of the mixture: (-)-epigallocatechin-3-gallat (EGCG) 0.10–3.0 nM; quercetin
0.11–3.3 nM; α-lipoic acid (LA) 0.16–4.9 nM; resvera rol 0. 5–1.5 nM; vitami C 0.89–26.8 nM; vitamin
E 0.06–1.9 nM; vitamin B6 0.02–0.5 nM; N-acetyl L-cystein 0.15–4.5 nM. The bar graph represents the
mean of three differe t experiments. * p < 0.05 and ** p < 0.01 vs. OGD (one-way ANOVA followed by
Dunnett’s multiple comparison test).
3.2. Pre-Treatment with PMM Prevents the Derangement of RelA Acetylation in Cortical Neurons Subjected
to OGD
Previous studies demonstrated that, in neuronal cultures exposed to OGD, the anti-apoptotic or
pro-apoptotic activity of NF-κB/p50-RelA relies on a different acetylation state of the RelA subunit,
the latter depending on the duration of OGD exposure. While a “protective”, preconditioning OGD
(1 h) promotes a general deacetylation of the RelA lysine residues, the lethal OGD (3 h) promotes the
deacetylation of RelA lysines with the exception of the 310 residue [10,12,13,16].
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In order to investigate the molecular mechanism associated with the neuroprotection,
we evaluated the capability of the lowest neuroprotective dose of the mixture to revert the derangement
of RelA acetylation. PMM at 0.884 pg/mL or vehicle were added to the cultured cortical neurons at
DIV 7 and maintained until 2 h after the OGD period. At the end, sister cultures were processed for
the separation of nuclear proteins or ChIP assay. Figure 2A shows the experimental protocol applied
for the ChIP, WB and co-IP analyses. Co-IP assays in nuclear extracts of cortical neurons exposed to
3 h OGD and 2 h recovery showed the ability of PMM to limit the RelA(K310) acetylation without
improving the general RelA deacetylation. As reported for the OGD precondition setting [10,12],
the ac-RelA(K310)/RelA ratio decreased, while the general ac-RelA/RelA remained lower than that in
control conditions (Figure 2B,C).
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Figure 2. Pre-treatment with PMM reduces ac-RelA(K310) acetylation in cortical neurons exposed
to OGD. (A) Experimental protocol for the Chromatin immunoprecipitation (ChIP) assay and Western
blot (WB) assay in cortical neurons. Cells were pre-treated with the PMM at DIV 7. At DIV 11, cells were
exposed to 3 h of OGD and then maintained in recovery medium for 2 h. The mixture was renewed at
every change of media. ChIP assays or WB analyses were performed at the end of the 2 h of recovery.
The lowest neuroprotective dose of the PMM was added to cells (EGCG 0.10 nM; quercetin 0.11 nM;
LA 0.16 nM; resveratrol 0.05 nM; vitamin C 0.89 nM; vitamin E 0.06 nM; vitamin B6 0.02 nM; N-acetyl
L-cysteine 0.15 nM). DMSO was used as vehicle in control cells and in neurons exposed to OGD.
(B,C) Co-IP assay of RelA acetylation in cortical neurons exposed to OGD. The acetylation levels of
total lysines (K) of RelA were unchanged after the treatment with the mixture when compared to
OGD-treated cells, while the treatment with the PMM restored the normal RelA(K310) acetylation.
The bar graphs represent the mean of three different experiments. * p < 0.05 and ** p < 0.01 vs.
OGD-treated cells (one-way ANOVA followed by Dunnett’s multiple comparison test).
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3.3. Pre-Treatment with PMM Reduces H3 Histone Acetylation at the Bim Promoter in Neurons Exposed
to OGD
As a marker of the epigenetic regulation of apoptosis, which precedes necrosis in neurons
exposed to OGD, we investigated the histone acetylation at the promoter of the pro-apoptotic gene
Bim [14], specifically targeted by the ac-RelA(K310) [12,16]. In line with previous data, the ChIP assay
demonstrated a specific increase of H3 acetylation (K9/18) at the Bim promoter in neurons exposed
to OGD [12,14,16]. The histone acetylation decreased in cells treated with the lowest neuroprotective
dose of the mixture (PMM at 0.884 pg/mL) (Figure 3).
Nutrients 2019, 11, 345 8 of 15 
Western blot (WB) assay in cortical neurons. Cells were pre-treated with the PMM at DIV 7. At DIV 
11, cells were exposed to 3 h of OGD and then maintained in recovery medium for 2 h. The mixture 
was renewed at every change of media. ChIP assays or WB analyses were performed at the end of the 
2 h of recovery. The lowest neuroprotective dose of the PMM was added to cells (EGCG 0.10 nM; 
quercetin 0.11 nM; LA 0.16 nM; resveratrol 0.05 nM; vitamin C 0.89 nM; vitamin E 0.06 nM; vitamin 
B6 0.02 nM; N-acetyl L-cysteine 0.15 nM). DMSO was used as vehicle in control cells and in neurons 
exposed to OGD. (B, C) Co-IP assay of RelA acetylation in cortical neurons exposed to OGD. The 
acetylation levels of total lysines (K) of RelA were unchanged after the treatment with the mixture 
when compared to OGD-treated cells, while the treatment with the PMM restored the normal 
RelA(K310) acetylation. The bar graphs represent the mean of three different experiments. * p < 0.05 
and ** p < 0.01 vs. OGD-treated cells (one-way ANOVA followed by Dunnett’s multiple comparison 
test). 
3.3. Pre-Treatment with PMM Reduces H3 Histone Acetylation at the Bim Promoter in Neurons Exposed to 
OGD. 
As a marker of the epigenetic regulation of apoptosis, which precedes necrosis in neurons 
exposed to OGD, we inv sti at d the histone acetylation at the promoter of the p -apoptotic gene 
Bim [14], specifically targeted by the ac-RelA(K310) [12,16]. In line with p evious data, the ChIP assay 
demonstrated a specific increase of H3 acetylation (K9/18) at the Bim omoter in neurons exposed 
to OGD [12,14,16]. The histone acetylation decreased in cells treated with the lowest neuroprotective 
dose of the mixture (PMM at 0.884 pg/mL) (Figur  3). 
 
Figure 3. Pre-treatment with PMM reduces H3 histone acetylation at the Bim promoter in neurons 
subjected to OGD. ChIP assay in cortical neurons exposed to OGD. Cells were pre-treated with the 
PMM at DIV 7. At DIV 11, cells were exposed to 3 h of OGD and then maintained in recovery medium 
for 2 h. The mixture was renewed at every change of media. The ChIP assay was performed at the 
end of the 2 h of recovery. The lowest neuroprotective dose of the PMM was added to cells (EGCG 
0.10 nM; quercetin 0.11 nM; LA 0.16 nM; resveratrol 0.05 nM; vitamin C 0.89 nM; vitamin E 0.06 nM; 
vitamin B6 0.02 nM; N-acetyl L-cysteine 0.15 nM). DMSO was used as vehicle in control cells and in 
neurons exposed to OGD. The ChIP assay revealed an epigenetic effect of the mixture in reducing the 
acetylation state of histones H3 on the promoter of the pro-apoptotic gene Bim. The bar graph 
represents the mean of three different experiments. * p < 0.05 vs. OGD-treated cells (one-way ANOVA 
followed by Dunnett’s multiple comparison test). 
3.4. Pre-Treatment with PMM Does Not Restore the Histone Acetylation Status in Cortical Neurons 
Subjected to OGD. 
Figure 3. Pre-treatment with PMM reduces H3 histone acetylation at the Bim promoter in neurons
subjected to OGD. ChIP assay in cortical neurons exposed to OGD. Cells were pre-treated with the
PMM at DIV 7. At DIV 11, cells were exposed to 3 h of OGD and then maintained in recovery medium
for 2 h. The mixture was renewed at every change of media. The ChIP assay was performed at the
end of the 2 h of recovery. The lowest neuroprotective dose of the PMM was added to cells (EGCG
0.10 nM; quercetin 0.11 nM; LA 0.16 nM; resveratrol 0.05 nM; vitamin C 0.89 nM; vitamin E 0.06 nM;
vitamin B6 0.02 nM; N-acetyl L-cysteine 0.15 nM). DMSO was used as vehicle in control cells and in
neurons exposed to OGD. The ChIP assay revealed an epigenetic effect of the mixture in reducing
the acetylation state of histones H3 on the promoter of the pro-apoptotic gene Bim. The bar graph
represents the mean of three different experiments. * p < 0.05 vs. OGD-treated cells (one-way ANOVA
followed by Dunnett’s multiple comparison test).
3.4. Pre-Treatment with PMM Does Not Restore the Histone Acetylation Status in Cortical Neurons Subjected
to OGD
We then evaluated the effect of PMM in modulating the acetylation state of histones in cortical
neurons subjected to OGD. The global H3 (K9–18) and H4 (K16) acetylation, measured by the WB
analyses of nuclear extracts, appeared reduced, in line with previous evidence obtained either in cells
exposed to OGD or in in vivo brain ischemia [16,26]. However, the general histone deacetylation was
not reversed by the PMM application at the lowest neuroprotective dose (0.884 pg/mL) (Figure 4A
and 4B), thus excluding a possible general inhibitory effect of PMM on HDAC activity.
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cortical neurons subjected to OGD. WB of acetylation levels of H3 (A) and H4 (B) i cortical neurons
exposed to OGD. Cells were pre-treated with the PMM at DIV 7. At DIV 11, cells were xposed to 3 h
of OGD and then maintained in recovery medium for 2 h. The mixture was ren wed at every change of
media. The WB assay was p rformed at the end of the 2 h of recovery. Th lowest neuroprotective dose
of the PMM was used (EGCG 0.10 nM; quercetin 0.11 nM; LA 0.16 nM; resveratrol 0.05 nM; vitamin C
0.89 nM; vitamin E 0.06 nM; vitami B6 0.02 nM; N-acetyl -cysteine 0.15 nM). DMSO was used as
a vehicle in control cells and neurons exposed to OGD. The acetylation levels of histones H3 and H4
did not return to control levels after treatment with the mixture. The bar graph represents the mean
of three different experiments. * p <0.05 and *** p < 0.001 vs. OGD-treated cells (one-way ANOVA
followed by Dunnett’s multiple comparison test).
4. Discussion
Here, we demonstrated the neuroprotective effect of a polyphenol-enriched nutrient supplement
in a cell-based del of ischemic stroke involving the primary cortical neurons exposed to l thal OGD.
Neuroprotection was associat d wi h cha ges the acetylation state of NF-κB/RelA. In our
experimental setting, we confirmed the aberrant acetylation of RelA after the lethal OGD exposure.
The PMM treatment was ble to reduce the ac-RelA(K310) acetylation without improving the
deacetylation of the other lysine residues. It can be inferred that PMM could induce a switch of RelA
from the “lethal pro-apoptotic” form to the “preconditioning protective” form [12]. By undergoing the
aberrant acetylation, RelA binds the pro-apoptotic Bim promoter [16], an event followed by specific
histone acetylation at the target gene promoter. The increased H3 acetylation at the Bim promoter is an
early marker of the triggered apoptotic process [16]. In the present work, we demonstrated that the
treatment of cells with PMM was able to limit the H3 acetylation at the Bim promoter, suggesting that
the mixture of bioactive components could regulate the expression of this pro-apoptotic gene (Figure 5).
In addition to changing the acetylation state of RelA, lethal ischemia produces a significant
reduction of H3 and H4 histone acetylation [16,26]. Our data confirmed the general reduction of
H3 and H4 histone acetylation after OGD exposure. In contrast to the effect produced by HDAC
inhibitors in models of brain ischemia [16,27,28], PMM did not restore the general histone acetylation.
This suggests that the supplement mixture acts as a HAT inhibitor, rather than a HDAC inhibitor.
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Figure 5. PMM-mediated defense from ischemic injury. During OGD, the activated RelA within the
p50/RelA dimer is in its aberrantly acetylated form, consisting of a hypoacetylated state with the
exception of the residue K310. In this condition, p50/RelA binds the pro-apoptotic Bim promoter,
an event followed by specific histone H3 acetylation at the target gene promoter. We demonstrated
that the pre-treatment of neurons with PMM was able to limit the RelA(K310) acetylation and
the H3 acetylation at the Bim promoter. Neither the general acetylation of RelA, nor the general
histone acetylation, were restored by the supplement mixture, suggesting that PMM acts as a histone
acetyltransferase (HAT) inhibitor, rather than a histone deacetylase (HDAC) inhibitor. We speculate
that the correction of the aberrant RelA acetylation in K310 could be promoted by components of
the mixture able to act as HAT inhibitors, including EGCG, quercetin and LA. Also, the activation
of the AMPK–sirtuin 1 pathway by EGCG, quercetin, LA, vitamin C, vitamin E, vitamin B6 and
N-acetyl-L-cysteine (NAC) could contribute to the ac-RelA(K310) deacetylation.
EGCG, one of the main components of the mixture, has been proposed to act as either an HDAC
inhibitor or a HAT inhibitor [29–32]. In accordance with the hypothesis that in our model EGCG could
work as a HAT inhibitor, Choi and colleagues reported that EGCG reduced ac-RelA(K310) acetylation
by directly inhibiting the activity of HAT enzymes, p300 and CPB [29]. However, it cannot be excluded
that, at concentrations higher than those used in our experimental setting, the EGCG inhibition of
HAT can lead to the reduction of histone acetylatio at the HDAC promoter, resulting in the inhibition
of HDAC expression. Several bioactive components of the mixture could act s HAT inhibitors,
thus contributing to the observed neuroprotective effect. Besides EGCG, among the compounds
present at higher concentrations, quercetin and LA inhibit p300/CBP [33,34] and have been reported to
exert neuroprotective effects in cellular and animal models of brain ischemia [17–21,35–41]. Therefore,
one of the possible mechanisms involved in the RelA regulation could very well be the inhibition of
p300/CBP by PMM (Figure 5).
Recently, we showed that the combination of MS-275 or valproate, two class-I HDAC inhibitors,
with resveratrol, an activator of the AMP-activated protein kinase (AMPK)–sirtuin 1 pathway, could
restore normal RelA acetylation and elicit neuroprotection in cortical neurons exposed to OGD and in
animal models of brain ischemia [16,27] or amyotrophic lateral sclerosis (ALS) [42]. In light of these
findings, we can speculate that the resveratrol present in the PMM, by activating the AMPK-sirtuin
1 pathway, could participate in ac-RelA(K310) deacetylation and work synergistically with other
compounds to limit NF-κB-mediated apoptosis [12,16,43] (Figure 5). Recent findings indicate that also
other molecules of the mixture, including EGCG, quercetin, LA, vitamin C, vitamin E, vitamin B6
and N-acetyl-L-cysteine (NAC) are able to activate the AMPK–sirtuin 1 pathway [44–55], suggesting
that these compounds could amplify the action of resveratrol. Future experiments will investigate the
effects of sirtuin-1 and AMPK inhibitors in blocking the neuroprotective activity of PMM.
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The broccoli extract present in the PMM could also contribute to the observed neuroprotective
effect. The isothiocyanate compound sulforaphane (1-isothiocyanato-4-methylsulfinylbutane), which is
highly produced in a variety of cruciferous vegetables (Brassica; e.g., broccoli), has been found to
protect hippocampal neurons against OGD at a concentration of 0.5 µM [56] and to inhibit HDAC
activity in mouse cortical neurons at 10–20 µM [57]. However, the lack of HDAC inhibitor-like effects
of PMM, i.e., the failure to increase the general acetylation of RelA and H3 (K9–18) and H4 (K16)
histones [16], might very well exclude the participation of sulforaphane to the synergistic effects of the
other compounds in modulating RelA acetylation.
In our experimental setting, the expected concentrations of the compounds present in the mixture
were thousands-fold lower than those found to be protective when individual compounds were tested
in neurons exposed to OGD [16,18,35,41,58–62]. Similarly, the compounds’ concentrations in the PMM
were remarkably lower than those able to inhibit HATs or activate the AMPK–sirtuin 1 pathway when
the bioactive components were tested individually [16,29,33,34,44–49,51]. The neuroprotective effect
and the epigenetic activity displayed by these molecules, despite their low concentrations, indicate
that a synergistic interaction between different bioactive components may occur in the PMM. Notably,
the beneficial effect occurs at concentrations in the nanomolar range, compatible with the predicted
brain levels of most of the bioactive components reachable at the recommended daily assumption dose
of PMM [63–71]. Although the approach to studying PMM has the limitation of not discriminating
the role of each specific compound separately, it offers the valuable advantage of evaluating the final
result of multiple nutritional supplements when administered in combination.
5. Conclusions
In conclusion, we demonstrated that a nutrient combination of antioxidant and multivitamin
supplements containing polyphenols could shape the acetylation of RelA and reduce the neuronal
vulnerability to conditions associated with oxygen and glucose deprivation. The protective activity of
PMM pretreatment suggests the beneficial effect of this supplementation in increasing resilience to
brain damage derived from potential ischemic events in treated subjects.
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